Veerhealth Care Ltd: FY26 Profit ₹0.54 Crore, Q4 Sees Loss

Veerhealth Care Ltd reported a net profit of ₹0.54 crore for the fiscal year ended March 31, 2026, on revenue from operations of ₹32.48 crore.

Reader Takeaway: Full-year profit rose, but Q4 net loss and rising costs signal caution.

What just happened

Veerhealth Care Ltd announced its audited financial results for the fourth quarter and full fiscal year ending March 31, 2026. The company reported an annual revenue of ₹32.48 crore, a significant increase from ₹16.87 crore in the previous fiscal year. Annual net profit also grew to ₹0.54 crore, up from ₹0.39 crore in the prior year.

However, the fourth quarter (Q4 FY26) ended with a net loss of ₹0.35 crore, a reversal from the ₹0.40 crore profit recorded in the third quarter (Q3 FY26).

Why this matters

The strong annual performance is overshadowed by the quarterly loss, indicating potential operational challenges or seasonality. The increase in the cost of goods sold, specifically 'Purchase of stock-in-trade', in Q4 FY26 suggests margin pressures that investors should monitor.

The backstory

Veerhealth Care operates in the pharmaceutical and healthcare sector, focusing on the manufacturing and marketing of pharmaceutical products. The company has been working to scale its operations and expand its product portfolio.

What changes now

Investors will be watching how the company manages its increased inventory costs and aims to return to profitability in the next quarter. The Board's decision not to recommend a dividend for FY26 signals a focus on reinvesting profits or conserving cash for operational needs.

Risks to watch

The primary risk is the sustainability of revenue growth against rising input costs, which led to the Q4 loss. Managing inventory efficiently and improving margins will be crucial. The company also faces competition within the broader healthcare sector.

Peer comparison

While direct peer comparisons require specific financial data for similar-sized companies, the trend of improving topline but facing margin pressures is not uncommon in the pharmaceutical sector, especially for smaller players dealing with procurement costs.

Context metrics (time-bound)

• FY26 Revenue: ₹32.48 crore (up from ₹16.87 crore in FY25)
• FY26 Net Profit: ₹0.54 crore (up from ₹0.39 crore in FY25)
• Q4 FY26 Net Loss: ₹0.35 crore (compared to Q3 FY26 profit of ₹0.40 crore)
• Q4 FY26 Purchase of stock-in-trade: ₹13.96 crore (up from ₹6.32 crore in Q3 FY26)

What to track next

Investors should monitor the company's quarterly earnings reports for Q1 FY27, focusing on revenue trends, profitability margins, and the management of 'Purchase of stock-in-trade' expenses to assess the impact of the recent Q4 performance and cost increases.